Bifidobacteria

  • SCIENTIFIC NAMES: Bifidobacterium adolescentis; Bifidobacterium animalis; Bifidobacterium bifidum; Bifidobacterium breve; Bifidobacterium infantis; Bifidobacterium lactis; Bifidobacterium longum
  • INDICATIONS: Diarrhea, atopic eczema, candidiasis, colds and flu, hepatitis, hypercholesterolemia, lactose intolerance, ulcerative colitis, pouchitis, irritable bowel syndrome
  • SYNONYM: Actinomycetaceae
  • CLASS: Immunomodulator, Probiotic
  • HALF-LIFE: N/A
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A

Immune-deficient subjects or those with mucosal disease may experience serious adverse effects.

Bifidobacterium is often combined with Lactobacillus, Saccharomyces or Streptococcus thermophilus.

Our database has 0 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe



Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of probiotics in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric